Impact of CD19 CAR Product on Resource Utilization through Day 28 for Large Cell Lymphoma

Key Points

• Resource utilization for CD19 CAR therapy showed significant insights by Day 28, impacting treatment protocols.
• Key metrics observed included hospitalization days and treatment dosage adjustments as answers to patient needs.
• Analysis of clinical data from large cell lymphoma patients revealed pertinent trends in resource allocation and therapeutic impact.
• Understanding resource use can help streamline CAR therapies in clinical practice, benefiting patient care and healthcare costs.